BIOAGE LABS, INC. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
BIOAGE LABS, INC. (BIOA) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of $2.41 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2026-03-24
- BIOAGE LABS, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2025 was $2.41M, a 3.70% increase from fiscal 2024.
- BIOAGE LABS, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2024 was $2.32M, a 29.43% increase from fiscal 2023.
- BIOAGE LABS, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2023 was $1.79M.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $2.41M 10-K · filed 2026-03-24 | |
| 2024-12-31 | $2.32M 10-K · filed 2026-03-24 | $3.63M 10-K · filed 2025-03-20 |
| 2023-12-31 | $1.79M 10-K · filed 2025-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |